Expert explains the true costs of genetic testing

April 30, 2018, University of Toronto
Credit: University of Toronto

From 23 and Me and Ancestry DNA to research laboratories, genome sequencing has become widely available, but better understanding is needed on when it should be used and whether it should be covered by health plans, says a U of T health economics professor.

"On the one hand, it's great to see the public becoming more aware of options for genetic testing, but one downside is that people start to think of sequencing as a 'miracle ,' and that we should screen for every possible future disease no matter what the cost," says Wendy Ungar a professor of economics at the Dalla Lana School of Public Health's Institute of Health Policy, Management and Evaluation.

While the technology has advanced rapidly in recent years, policy has yet to keep up, she says. Some of the questions that need to be explored include whether all genetic testing should be covered by provincial or just a few.  Health-care systems like Ontario's have constrained budgets, so understanding what types or topics of genetic testing are cost-effective, is of major interest to the Ministry of Health and Long-term Care.

"We have to look at what makes sense in terms of value, and not simply whether a test costs $100 or even $1,000," says Ungar, who is also director of technology assessment at Sick Kids. "Is the test supported by scientific and economic evidence and will it truly help patients and clinicians in terms of treating or preventing disease – these are the types of questions we need to consider, not just the dollar amount."

Ungar is chair of Health Quality Ontario's Ontario Genetics Advisory Committee, also known as OGAC, where she and her colleagues are working to help the province and the ministry gain a better understanding of the value of different genetic tests and how or if they should be funded.

"We prioritize different topics of testing, such as carrier screening and non-invasive prenatal testing among others, and look at where there is the most need or demand," Ungar says. "Once these tests are prioritized, a health technology assessment and budget impact analysis are conducted, and the results are deliberated by the committee."

One topic of testing currently under deliberation is non-invasive prenatal screening.

"A pregnant woman actually has fetal DNA circulating in her bloodstream, so a simple blood draw can be analyzed to look at whether certain conditions may be present in the fetus," says Ungar.

Credit: University of Toronto

This test can identify chromosomal abnormalities related to trisomies such as Down syndrome and is currently only funded for women who are pregnant and considered high risk, such as those over the age of 40 or those with a family history of trisomies and other chromosomal abnormalities. The test, however, is not publicly funded for everyone. 

"Amniocentesis and chorionic villus sampling are other testing options available, but they pose a risk to the fetus and the pregnancy because they are much more invasive," Ungar says.

The committee also needs to consider the care pathway for prenatal care and how it might change if the decision was made to make the test available to all pregnant women.

 "At what stage of care should we offer the test – at the first ultrasound or as part of the first blood test? These are further questions we are taking into account as part of the review," Ungar says.

A funding recommendation for the test is expected to be posted to the HQO website for public feedback in May.

As for whether we should be more cautious about newer generations of such as , Ungar explains that patients can have several potentially pathogenic variants appear that are not related to the original reason for undergoing a genetic test.

These variants can show risks for breast cancer or colon cancer or even Huntington's disease. Once disclosed to the patient, they can trigger further costs to the health system as patients seek care from specialists to reduce their risks for such diseases.

 "It is not just a single test, a single result, or a single patient – there are a whole host of cascading effects that we need to consider, including effects on the patients themselves and their family members."

Explore further: ACOG issues recommendations on prenatal screening

Related Stories

ACOG issues recommendations on prenatal screening

March 4, 2016
(HealthDay)—Recommendations on screening for genetic disorders and fetal aneuploidy have been updated, according to two Practice Bulletins published online March 3 in Obstetrics & Gynecology.

Not all genetic tests should be publicly funded — here's why

February 1, 2018
New genetic technologies hold great promise in their potential to treat patients based on their individual genetic information. Advances in mapping the human genome mean the cost of doing a genetic test has fallen dramatically, ...

Majority of women prefer non-invasive testing for trisomy 21

December 15, 2017
(HealthDay)—The majority of both high-risk and intermediate-risk women prefer a non-invasive cell-free prenatal DNA screening (NIPT) as a secondary screening test for trisomy 21, according to a study published online Nov. ...

New technique could expand number of diseases detected by noninvasive prenatal testing

November 9, 2015
Researchers at the University of California, San Diego School of Medicine developed a method to expand the types of chromosomal abnormalities that noninvasive prenatal testing (NIPT) can detect. The study, published November ...

What genetic testing information to expect when you're expecting

February 2, 2018
Experts have recommended greater support and choice of information for pregnant women who decide to have genetic testing.

Non-invasive first trimester blood test reliably detects Down's syndrome

June 7, 2013
New research has found that routine screening using a non-invasive test that analyzes fetal DNA in a pregnant woman's blood can accurately detect Down's syndrome and other genetic fetal abnormalities in the first trimester. ...

Recommended for you

Identifying Crohn's disease risk factors in the Ashkenazi Jewish population

May 25, 2018
It is estimated that one in three individuals of Ashkenazi Jewish (AJ) descent carry mutations that increase their risk for certain genetic diseases. For instance, Crohn's, a highly heritable inflammatory bowel disease, is ...

How do insects survive on a sugary diet?

May 25, 2018
There's a reason parents tell their kids to lay off the sugar: too much isn't good for you.

Regulatory mutations missed in standard genetic screening lead to congenital diseases

May 25, 2018
Researchers have identified a type of genetic aberration to be the cause of certain neurodevelopmental disorders and congenital diseases, such as autism and congenital heart disease, which are undetectable by conventional ...

New chromosome study can lead to personalised counselling of pregnant women

May 25, 2018
Foetuses with a so-called new balanced chromosomal aberration have a higher risk of developing brain disorders such as autism and mental retardation than previously anticipated. The risk is 20 per cent for foetuses with these ...

New findings on autism-related disorder

May 24, 2018
In a study published today in Nature, Marc Bühler and his group at the Friedrich Miescher Institute for Biomedical Research (FMI) have taken a major step forward in elucidating the mechanisms underlying a disorder known ...

Genome study presents new way to track historical demographics of US populations

May 24, 2018
Sharon Browning of the University of Washington and colleagues developed a method to estimate historical effective population size, which is the number of individuals who pass on their genes to the next generation, to reveal ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.